Literature DB >> 2824042

Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer.

U Berger1, P Wilson, R A McClelland, K Colston, M R Haussler, J W Pike, R C Coombes.   

Abstract

We have developed an immunocytochemical technique to visualize the receptor for 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] in cryostat sections of human breast tumors and normal human breast tissue utilizing a monoclonal antibody (9A7 gamma) to chick intestinal receptor which recognizes mammalian 1,25(OH)2D3 receptor. Specific staining was observed in the nuclei of tumor cells. Previous studies by our group have shown that a high proportion of breast tumors bind radiolabeled 1,25(OH)2D3 and we have confirmed this, demonstrating immunocytochemical 1,25(OH)2D3 receptor in 43 of 55 (78%) of breast carcinomas. No correlation with the presence of immunostainable estrogen receptor was found in these breast cancer specimens. Sections of normal breast showed immunoreactivity in the nuclei of epithelial cells of the lobules and ducts. Our results demonstrate that the receptor for 1,25(OH)2D3 resides predominantly in the nucleus of breast carcinoma cells. The reason for its prominent expression in breast cancers is not yet known but may be related to growth regulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.

Authors:  Erin L Milliken; Xiaoxue Zhang; Chris Flask; Jeffrey L Duerk; Paul N MacDonald; Ruth A Keri
Journal:  Cancer Lett       Date:  2005-08-22       Impact factor: 8.679

2.  The association between vitamin D receptor expression and prolonged overall survival in breast cancer.

Authors:  Nina Ditsch; Bettina Toth; Doris Mayr; Miriam Lenhard; Julia Gallwas; Tobias Weissenbacher; Christian Dannecker; Klaus Friese; Udo Jeschke
Journal:  J Histochem Cytochem       Date:  2011-11-21       Impact factor: 2.479

Review 3.  The regulatory role of miRNAs on VDR in breast cancer.

Authors:  Tatyana Singh; Brian D Adams
Journal:  Transcription       Date:  2017-06-09

4.  Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.

Authors:  Nair Lopes; Bárbara Sousa; Diana Martins; Madalena Gomes; Daniella Vieira; Luiz A Veronese; Fernanda Milanezi; Joana Paredes; José L Costa; Fernando Schmitt
Journal:  BMC Cancer       Date:  2010-09-11       Impact factor: 4.430

5.  Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma.

Authors:  Nina Ditsch; Doris Mayr; Miriam Lenhard; Carolin Strauss; Andrea Vodermaier; Julia Gallwas; Doris Stoeckl; Monika Graeser; Tobias Weissenbacher; Klaus Friese; Udo Jeschke
Journal:  Oncol Lett       Date:  2012-07-13       Impact factor: 2.967

6.  1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  Y Iino; M Yoshida; N Sugamata; M Maemura; S Ohwada; T Yokoe; T Ishikita; R Horiuchi; Y Morishita
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Vitamin D: Actions for the new millennium.

Authors:  H Lai; R Pandey; S K Aggarwal
Journal:  Indian J Clin Biochem       Date:  2000-08

8.  Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells.

Authors:  T Vink-van Wijngaarden; H A Pols; C J Buurman; J C Birkenhäger; J P van Leeuwen
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

9.  25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.

Authors:  Ulrika Segersten; Pernille Kaae Holm; Peyman Björklund; Ola Hessman; Hans Nordgren; Lise Binderup; Göran Akerström; Per Hellman; Gunnar Westin
Journal:  Breast Cancer Res       Date:  2005-10-06       Impact factor: 6.466

10.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.